PTC124针对的是由无意义突变引起的遗传疾病
Ellen M Welch1, Elisabeth R Barton, Jin Zhuo
1PTC Therapeutics, 100 Corporate Court, South Plainfield, New Jersey 07080, USA.
Nature
|April 24, 2007
概括
一种新的药物,PTC124,可以选择性地诱导核糖体读取过早停止的编码子,从而潜在地治疗遗传疾病. 这种药物促进蛋白质的产生,并在临床前模型中拯救肌肉功能,具有良好的耐受性.
科学领域:
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 无意义的突变导致过早的转化终止,导致5-70%的遗传性疾病.
- 恢复蛋白质合成,即使在低水平,也可以显著减少疾病的严重程度,如在囊性纤维化中所见.
研究的目的:
- 为了确定一种可以选择性地抑制过早终止子的药物.
- 评估已识别的药物PTC124的疗效和安全性,用于治疗遗传疾病.
主要方法:
- 鉴定并优化了PTC124用于选择性核糖体读透早期终结编码子.
- 评估了PTC124在具有无意义等位基因的人类和小鼠细胞中促进消毒素生成的能力.
- 在接受PTC124.4治疗的mdx小鼠中评估了条纹肌肉功能恢复.
主要成果:
- PTC124 选择性诱导的核糖体读取过早终结的编码子.
- 在肌肉细胞中促进了双素的产生,在mdx小鼠中恢复了条纹肌肉功能.
- 在有效剂量下,PTC124在动物模型中表现出良好的耐受性.
结论:
- PTC124显示出治疗各种由无意义突变引起的遗传疾病的潜力.
- 该药物的选择性,疗效和有利的药理学特征支持其广泛的临床潜力.
相关概念视频
Mutations
Overview
Translation
Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Nonsense-mediated mRNA Decay
The Upf proteins that carry out nonsense-mediated decay (NMD) are found in all eukaryotic organisms, including humans. Each protein has an individual role, but they need to work in collaboration. Upf1 is an ATP-dependent RNA helicase that unwinds the RNA helix. Because Upf1 can unwind any RNA, Upf2 and Upf3 are required to help Upf1 discriminate between nonsense and normal mRNAs.
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...
Alternative RNA Splicing
Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Nonsense-mediated mRNA Decay
The Upf proteins that carry out nonsense-mediated decay (NMD) are found in all eukaryotic organisms, including humans. Each protein has an individual role, but they need to work in collaboration. Upf1 is an ATP-dependent RNA helicase that unwinds the RNA helix. Because Upf1 can unwind any RNA, Upf2 and Upf3 are required to help Upf1 discriminate between nonsense and normal mRNAs.
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...


